- A examine has discovered that therapy with semaglutide led to decreased triptan utilization in ladies.
- Nevertheless, no vital impact was noticed in males with obese or weight problems.
- Specialists say reductions in irritation or intracranial strain might play a job.
- Intercourse-related variations in how the physique handles semaglutide additionally look like vital.
- Extra analysis is required earlier than semaglutide might be advisable as a migraine therapy.
A latest nationwide examine in Denmark has revealed that ladies who begin utilizing semaglutide, a well-liked treatment prescribed for weight reduction, could expertise a lower within the want for normal migraine remedies.
The researchers discovered that females utilizing semaglutide had a noticeable discount of their use of a category of medicine known as triptans.
Researchers from the College of Southern Denmark collaborated with Novo Nordisk, the pharmaceutical firm behind semaglutide (marketed as Wegovy for weight reduction and Ozempic for diabetes management), to investigate information from Danish well being registries.
These registers comprise complete well being info on your complete inhabitants, enabling an in depth examination of treatment use patterns.
The examine targeted on adults who started semaglutide therapy for weight management between December 1, 2022, and June 30, 2024. It included almost 150,000 individuals who began semaglutide through the examine interval, of whom about two-thirds had been females.
For every particular person, the researchers tracked their use of triptans — the medicine generally taken for acute migraine reduction — for 2 years earlier than beginning semaglutide and for one 12 months afterward. This method enabled the researchers to look at adjustments over time and to check triptan use earlier than and after semaglutide initiation.
The staff used statistical fashions to look at month-to-month triptan consumption, measured in outlined every day doses, among the many contributors.
Additionally they seemed on the variety of new triptan customers through the examine and analyzed variations amongst individuals who had already been utilizing triptans earlier than beginning semaglutide.
To raised perceive who was most affected, the researchers broke down the information by intercourse, age teams, how persistently folks remained on semaglutide, and whether or not they had beforehand used preventive migraine medicines.
General, round 4.6% of the people used triptans through the examine interval.
Earlier than starting semaglutide, it was discovered that triptan use was on the rise amongst contributors.
Nevertheless, after beginning the treatment, this pattern reversed, and triptan use started to say no step by step over the next 12 months.
On the one-year mark, there was a modest however clear discount in triptan consumption in comparison with what would have been anticipated based mostly on earlier traits.
This lower was primarily seen in individuals who had been already utilizing triptans earlier than beginning semaglutide, suggesting that the drug may scale back the necessity for migraine reduction in these with a historical past of migraine.
There was no vital change within the variety of new triptan customers, nevertheless, indicating that semaglutide doesn’t seem to stop new instances of migraine from creating.
When evaluating men and women, the examine additionally discovered that females skilled an 8% discount in triptan use after beginning semaglutide, whereas males confirmed no vital change. This sex-specific impact could also be linked to variations in how men and women reply to semaglutide, together with sometimes better weight reduction amongst females.
Age additionally performed a job, with the most important reductions in triptan use seen in youthful adults aged 18 to 35.
Moreover, individuals who had beforehand taken preventive migraine medicines noticed a extra pronounced lower of their want for triptans.
The researchers additional noticed that the adjustments in triptan use occurred step by step slightly than instantly after beginning semaglutide, suggesting a sluggish however regular enchancment in migraine symptoms over time.
Whereas the precise causes for these findings are usually not absolutely understood, a number of components may contribute.
Tom Lavin, MD, a board licensed surgeon and founding father of the telehealth firm yourEra, mentioned that inflammation and intracranial pressure could play a job, given how GLP-1 medicines operate within the physique and mind. Lavin wasn’t concerned within the examine.
“GLP‑1 medicines like semaglutide scale back irritation all through the physique, together with within the mind,” he informed Healthline. “Neuroinflammation is a significant driver of migraine, so decreasing irritation can considerably scale back each the frequency and severity of complications.”
These medicines additionally result in gradual weight reduction, which may scale back intracranial strain.
“Elevated strain contained in the cranium is linked to sure headache disorders, so decreasing that strain can immediately enhance migraine signs,” Lavin mentioned.
GLP‑1 medicines work together with a number of mind areas concerned in migraine pathways, he added, together with the hypothalamus, brainstem facilities just like the nucleus tractus solitarius, and reward circuits.
In response to Lavin, these programs all have an effect on irritation, ache signaling, and hormonal regulation, which may contribute to migraine exercise.
Jill White, PharmD, CEO of Innovate Wellness, informed Healthline that “even a modest discount in triptan utilization could possibly be significant for migraine sufferers.” White wasn’t concerned within the examine.
Decrease triptan use might imply sufferers are having fewer assaults, experiencing much less extreme assaults, or relying much less on rescue treatment, White informed Healthline.
“That is vital as a result of frequent triptan use can contribute to medication-overuse headache and decreased high quality of life,” mentioned White.
“If GLP-1 receptor agonists scale back migraine burden not directly whereas concurrently bettering obesity-related comorbidities equivalent to sleep apnea, hypertension, insulin resistance, and systemic inflammation, some sufferers could expertise broad neurologic and metabolic advantages concurrently,” she added.
White additional famous the significance of the sex-specific findings, discussing how quite a lot of components, equivalent to variations in hormonal influences, immune signaling, distribution of fatty tissues, sensitivity of the CGRP pathway, and hypothalamic regulation, may affect the upper frequency of migraine in females.
“It’s doable that GLP-1-mediated metabolic or inflammatory enhancements work together otherwise with feminine neuroendocrine physiology, resulting in better observable profit in ladies,” mentioned White.
It may additionally be that females acquiring obesity treatments have the next baseline migraine prevalence or larger triptan utilization, she mentioned, making it simpler to detect reductions in utilization.
White concluded her remarks by saying, “The findings add to a rising physique of proof suggesting GLP-1 receptor agonists could have broader neurologic and anti inflammatory results past weight reduction alone.”
Whereas extra analysis is required earlier than GLP-1s might be advisable as a migraine remedy, this examine affords the promise that semaglutide may additionally ease the burden of migraine for a lot of females.
